David A. Scheinberg - Publications

Affiliations: 
Weill Cornell Medical College, New York, NY, United States 
Area:
Biochemistry

248 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2020 Dao T, Klatt MG, Korontsvit T, Mun SS, Guzman S, Mattar M, Zivanovic O, Kyi CK, Socci ND, O'Cearbhaill RE, Scheinberg DA. Impact of tumor heterogeneity and microenvironment in identifying neoantigens in a patient with ovarian cancer. Cancer Immunology, Immunotherapy : Cii. PMID 33123756 DOI: 10.1007/s00262-020-02764-9  1
2020 Cheal SM, McDevitt MR, Santich BH, Patel M, Yang G, Fung EK, Veach DR, Bell M, Ahad A, Vargas DB, Punzalan B, Pillarsetty NVK, Xu H, Guo HF, Monette S, ... ... Scheinberg DA, et al. Alpha radioimmunotherapy using Ac-proteus-DOTA for solid tumors - safety at curative doses. Theranostics. 10: 11359-11375. PMID 33052220 DOI: 10.7150/thno.48810  0.72
2020 Krebs S, Dacek MM, Carter LM, Scheinberg DA, Larson SM. CAR Chase: Where Do Engineered Cells Go in Humans? Frontiers in Oncology. 10: 577773. PMID 33042849 DOI: 10.3389/fonc.2020.577773  0.32
2020 Klatt MG, Mack KN, Bai Y, Aretz ZE, Nathan LI, Mun SS, Dao T, Scheinberg DA. Solving an MHC allele specific bias in the reported immunopeptidome. Jci Insight. PMID 32897882 DOI: 10.1172/jci.insight.141264  0.48
2020 Gejman RS, Jones HF, Klatt MG, Chang AY, Oh CY, Chandran SS, Korontsvit T, Zakahleva V, Dao T, Klebanoff CA, Scheinberg DA. Identification of the targets of T cell receptor therapeutic agents and cells by use of a high throughput genetic platform. Cancer Immunology Research. PMID 32184297 DOI: 10.1158/2326-6066.CIR-19-0745  1
2020 Urbanska AM, Khanin R, Alidori S, Wong S, Mello BP, Almeida BA, Chen F, Ma K, Turker MZ, Korontsvit T, Scheinberg DA, Zanzonico PB, Wiesner U, Bradbury MS, Quinn TP, et al. A Genomic Profile of Local Immunity in the Melanoma Microenvironment Following Treatment with α Particle-Emitting Ultrasmall Silica Nanoparticles. Cancer Biotherapy & Radiopharmaceuticals. PMID 32013538 DOI: 10.1089/cbr.2019.3150  0.72
2020 Mondello P, Tadros S, Teater M, Fontan L, Chang AY, Jain N, Yang H, Singh S, Ying HY, Chu CS, Ma MCJ, Toska E, Alig S, Durant M, de Stanchina E, ... ... Scheinberg DA, et al. Selective inhibition of HDAC3 targets synthetic vulnerabilities and activates immune surveillance in lymphoma. Cancer Discovery. PMID 31915197 DOI: 10.1158/2159-8290.CD-19-0116  0.48
2019 Oh CY, Klatt MG, Bourne C, Dao T, Dacek MM, Brea EJ, Mun SS, Chang AY, Korontsvit T, Scheinberg DA. ALK and RET inhibitors promote HLA class I antigen presentation and unmask new antigens within the tumor immunopeptidome. Cancer Immunology Research. PMID 31540894 DOI: 10.1158/2326-6066.CIR-19-0056  1
2019 Dao T, Mun SS, Scott AC, Jarvis CA, Korontsvit T, Yang Z, Liu L, Klatt MG, Guerreiro M, Selvakumar A, Brea EJ, Oh C, Liu C, Scheinberg DA. Depleting T regulatory cells by targeting intracellular Foxp3 with a TCR mimic antibody. Oncoimmunology. 8: 1570778. PMID 31143508 DOI: 10.1080/2162402X.2019.1570778  1
2018 Gejman RS, Chang AY, Jones HF, DiKun K, Hakimi AA, Schietinger A, Scheinberg DA. Rejection of immunogenic tumor clones is limited by clonal fraction. Elife. 7. PMID 30499773 DOI: 10.7554/eLife.41090  1
2018 Mondello P, Brea EJ, De Stanchina E, Toska E, Chang AY, Fennell M, Seshan V, Garippa R, Scheinberg DA, Baselga J, Wendel HG, Younes A. Panobinostat acts synergistically with ibrutinib in diffuse large B cell lymphoma cells with MyD88 L265 mutations. Jci Insight. 3. PMID 30429379 DOI: 10.1172/jci.insight.125568  0.48
2018 Mulvey JJ, Littmann ER, Ling L, McDevitt MR, Pamer EG, Scheinberg DA. The effects of amine-modified single-walled carbon nanotubes on the mouse microbiota. International Journal of Nanomedicine. 13: 5275-5286. PMID 30237714 DOI: 10.2147/IJN.S168554  0.72
2018 Maslak PG, Dao T, Bernal Y, Chanel SM, Zhang R, Frattini M, Rosenblat T, Jurcic JG, Brentjens RJ, Arcila ME, Rampal R, Park JH, Douer D, Katz L, Sarlis N, ... ... Scheinberg DA, et al. Phase 2 trial of a multivalent WT1 peptide vaccine (galinpepimut-S) in acute myeloid leukemia. Blood Advances. 2: 224-234. PMID 29386195 DOI: 10.1182/bloodadvances.2017014175  0.48
2017 Zauderer MG, Tsao AS, Dao T, Panageas KS, Lai WV, Rimner A, Rusch VW, Adusumilli PS, Ginsberg MS, Gomez DR, Rice DC, Mehran R, Scheinberg DA, Krug LM. A Randomized Phase II Trial of Adjuvant Galinpepimut-S, WT-1 Analog Peptide Vaccine, after Multimodality Therapy for Patients with Malignant Pleural Mesothelioma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 28972039 DOI: 10.1158/1078-0432.CCR-17-2169  0.48
2017 Casey E, Bournazos S, Mo G, Mondello P, Tan KS, Ravetch JV, Scheinberg DA. A new mouse expressing human Fcγ receptors to better predict therapeutic efficacy of human anti-cancer antibodies. Leukemia. PMID 28924242 DOI: 10.1038/leu.2017.293  0.48
2017 Chang AY, Dao T, Gejman RS, Jarvis CA, Scott A, Dubrovsky L, Mathias MD, Korontsvit T, Zakhaleva V, Curcio M, Hendrickson RC, Liu C, Scheinberg DA. A therapeutic T cell receptor mimic antibody targets tumor-associated PRAME peptide/HLA-I antigens. The Journal of Clinical Investigation. 127: 3557. PMID 28862643 DOI: 10.1172/JCI96860  1
2017 Alidori S, Thorek DLJ, Beattie BJ, Ulmert D, Almeida BA, Monette S, Scheinberg DA, McDevitt MR. Carbon nanotubes exhibit fibrillar pharmacology in primates. Plos One. 12: e0183902. PMID 28846728 DOI: 10.1371/journal.pone.0183902  0.72
2017 Mathias MD, Sockolosky JT, Chang AY, Tan KS, Liu C, Garcia KC, Scheinberg DA. CD47 blockade enhances therapeutic activity of TCR mimic antibodies to ultra low density cancer epitopes. Leukemia. PMID 28745331 DOI: 10.1038/leu.2017.223  1
2017 Chang AY, Dao T, Gejman RS, Jarvis CA, Scott A, Dubrovsky L, Mathias MD, Korontsvit T, Zakhaleva V, Curcio M, Hendrickson RC, Liu C, Scheinberg DA. A therapeutic T cell receptor mimic antibody targets tumor-associated PRAME peptide/HLA-I antigens. The Journal of Clinical Investigation. PMID 28628042 DOI: 10.1172/JCI92335  0.48
2017 Mondello P, Brea EJ, De Stanchina E, Toska E, Chang AY, Fennell M, Seshan V, Garippa R, Scheinberg DA, Baselga J, Wendel HG, Younes A. Panobinostat acts synergistically with ibrutinib in diffuse large B cell lymphoma cells with MyD88 L265 mutations. Jci Insight. 2: e90196. PMID 28352655 DOI: 10.1172/jci.insight.90196  0.48
2017 Dao T, Korontsvit T, Zakhaleva V, Jarvis C, Mondello P, Oh C, Scheinberg DA. An immunogenic WT1-derived peptide that induces T cell response in the context of HLA-A*02:01 and HLA-A*24:02 molecules. Oncoimmunology. 6: e1252895. PMID 28344864 DOI: 10.1080/2162402X.2016.1252895  1
2017 Şenbabaoğlu Y, Gejman RS, Winer AG, Liu M, Van Allen EM, de Velasco G, Miao D, Ostrovnaya I, Drill E, Luna A, Weinhold N, Lee W, Manley BJ, Khalil DN, Kaffenberger SD, ... ... Scheinberg DA, et al. Erratum to: Tumor immune microenvironment characterization in clear cell renal cell carcinoma identifies prognostic and immunotherapeutically relevant messenger RNA signatures. Genome Biology. 18: 46. PMID 28249590 DOI: 10.1186/s13059-017-1180-8  0.48
2017 Scheinberg DA, Grimm J, Heller DA, Stater EP, Bradbury M, McDevitt MR. Advances in the clinical translation of nanotechnology. Current Opinion in Biotechnology. 46: 66-73. PMID 28187340 DOI: 10.1016/j.copbio.2017.01.002  0.72
2017 Mondello P, Derenzini E, Asgari Z, Philip J, Brea EJ, Seshan V, Hendrickson RC, de Stanchina E, Scheinberg DA, Younes A. Dual inhibition of histone deacetylases and phosphoinositide 3-kinase enhances therapeutic activity against B cell lymphoma. Oncotarget. PMID 28147336 DOI: 10.18632/oncotarget.14876  0.48
2016 Şenbabaoğlu Y, Gejman RS, Winer AG, Liu M, Van Allen EM, de Velasco G, Miao D, Ostrovnaya I, Drill E, Luna A, Weinhold N, Lee W, Manley BJ, Khalil DN, Kaffenberger SD, ... ... Scheinberg DA, et al. Tumor immune microenvironment characterization in clear cell renal cell carcinoma identifies prognostic and immunotherapeutically relevant messenger RNA signatures. Genome Biology. 17: 231. PMID 27855702 DOI: 10.1186/s13059-016-1092-z  0.48
2016 Dubrovsky L, Brea EJ, Pankov D, Casey E, Dao T, Liu C, Scheinberg DA. Mechanisms of leukemia resistance to antibody dependent cellular cytotoxicity. Oncoimmunology. 5: e1211221. PMID 27757306 DOI: 10.1080/2162402X.2016.1211221  1
2016 Brea EJ, Oh CY, Manchado E, Budhu S, Gejman RS, Mo G, Mondello P, Han JE, Jarvis CA, Ulmert D, Xiang Q, Chang AY, Garippa RJ, Merghoub T, Wolchok JD, ... ... Scheinberg DA, et al. Kinase regulation of Human MHC Class I Molecule Expression on Cancer Cells. Cancer Immunology Research. PMID 27680026 DOI: 10.1158/2326-6066.CIR-16-0177  1
2016 Alidori S, Bowman RL, Yarilin D, Romin Y, Barlas A, Mulvey JJ, Fujisawa S, Xu K, Ruggiero A, Riabov V, Thorek DL, Ulmert HD, Brea EJ, Behling K, Kzhyshkowska J, ... ... Scheinberg DA, et al. Deconvoluting hepatic processing of carbon nanotubes. Nature Communications. 7: 12343. PMID 27468684 DOI: 10.1038/ncomms12343  0.72
2016 Röhrig F, Vorlová S, Hoffmann H, Wartenberg M, Escorcia FE, Keller S, Tenspolde M, Weigand I, Gätzner S, Manova K, Penack O, Scheinberg DA, Rosenwald A, Ergün S, Granot Z, et al. VEGF-ablation therapy reduces drug delivery and therapeutic response in ECM-dense tumors. Oncogene. PMID 27270432 DOI: 10.1038/onc.2016.182  0.72
2016 Behling K, DiGialleonardo V, Maguire WF, Heeb LE, Hassan IF, Veach DR, Keshari KR, Gutin PH, Scheinberg DA, McDevitt MR. Remodelling the vascular microenvironment of glioblastoma with alpha-particles. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. PMID 27261519 DOI: 10.2967/jnumed.116.173559  0.72
2016 Behling K, Maguire WF, Puebla JC, Sprinkle SR, Ruggiero A, O'Donoghue J, Gutin PH, Scheinberg DA, McDevitt MR. Vascular targeted radioimmunotherapy for the treatment of glioblastoma. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. PMID 27127217 DOI: 10.2967/jnumed.115.171371  0.72
2016 Y Chang A, Gejman R, J Brea E, Y Oh C, Mathias M, Pankov D, Casey E, Dao T, Scheinberg DA. Opportunities and challenges for TCR mimic antibodies in cancer therapy. Expert Opinion On Biological Therapy. PMID 27094818 DOI: 10.1080/14712598.2016.1176138  0.32
2016 Alidori S, Akhavein N, Thorek DL, Behling K, Romin Y, Queen D, Beattie BJ, Manova-Todorova K, Bergkvist M, Scheinberg DA, McDevitt MR. Targeted fibrillar nanocarbon RNAi treatment of acute kidney injury. Science Translational Medicine. 8: 331ra39. PMID 27009268 DOI: 10.1126/scitranslmed.aac9647  0.72
2016 Dubrovsky L, Dao T, Gejman RS, Brea EJ, Chang AY, Oh CY, Casey E, Pankov D, Scheinberg DA. T cell receptor mimic antibodies for cancer therapy. Oncoimmunology. 5: e1049803. PMID 26942058 DOI: 10.1080/2162402X.2015.1049803  1
2016 Dubrovsky L, Brea EJ, Pankov D, Casey E, Dao T, Liu C, Scheinberg DA. Mechanisms of leukemia resistance to antibody dependent cellular cytotoxicity Oncoimmunology. DOI: 10.1080/2162402X.2016.1211221  1
2016 Dubrovsky L, Dao T, Gejman RS, Brea EJ, Chang AY, Oh CY, Casey E, Pankov D, Scheinberg DA. T cell receptor mimic antibodies for cancer therapy Oncoimmunology. 5. DOI: 10.1080/2162402X.2015.1049803  0.32
2015 Ataie N, Xiang J, Cheng N, Brea EJ, Lu W, Scheinberg DA, Liu C, Ng HL. Structure of a TCR mimic antibody with target predicts pharmacogenetics. Journal of Molecular Biology. PMID 26688548 DOI: 10.1016/j.jmb.2015.12.002  0.32
2015 Dao T, Pankov D, Scott A, Korontsvit T, Zakhaleva V, Xu Y, Xiang J, Yan S, de Morais Guerreiro MD, Veomett N, Dubrovsky L, Curcio M, Doubrovina E, Ponomarev V, Liu C, ... ... Scheinberg DA, et al. Therapeutic bispecific T-cell engager antibody targeting the intracellular oncoprotein WT1. Nature Biotechnology. PMID 26389576 DOI: 10.1038/nbt.3349  1
2015 Matson ML, Villa CH, Ananta JS, Law JJ, Scheinberg DA, Wilson LJ. Encapsulation of α-Particle-Emitting 225Ac3+ Ions Within Carbon Nanotubes. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. 56: 897-900. PMID 25931476 DOI: 10.2967/jnumed.115.158311  1
2015 Zanzonico P, Carrasquillo JA, Pandit-Taskar N, O’Donoghue JA, Humm JL, Smith-Jones P, Ruan S, Divgi C, Scott AM, Kemeny NE, Fong Y, Wong D, Scheinberg D, Ritter G, Jungbluth A, et al. PET-based compartmental modeling of 124I-A33 antibody: quantitative characterization of patient-specific tumor targeting in colorectal cancer European Journal of Nuclear Medicine and Molecular Imaging. DOI: 10.1007/s00259-015-3061-2  1
2014 McDevitt MR, Scheinberg DA. Fibrillous carbon nanotube: An unexpected journey Critical Reviews in Oncogenesis. 19: 261-268. PMID 25271434 DOI: 10.1615/CritRevOncog.2014011442  1
2014 Mulvey JJ, Feinberg EN, Alidori S, McDevitt MR, Heller DA, Scheinberg DA. Synthesis, pharmacokinetics, and biological use of lysine-modified single-walled carbon nanotubes International Journal of Nanomedicine. 9: 4245-4255. PMID 25228803 DOI: 10.2147/IJN.S66050  1
2014 Villa JC, Chiu D, Brandes AH, Escorcia FE, Villa CH, Maguire WF, Hu CJ, de Stanchina E, Simon MC, Sisodia SS, Scheinberg DA, Li YM. Nontranscriptional role of Hif-1α in activation of γ-secretase and notch signaling in breast cancer. Cell Reports. 8: 1077-92. PMID 25131208 DOI: 10.1016/j.celrep.2014.07.028  1
2014 Maguire WF, McDevitt MR, Smith-Jones PM, Scheinberg DA. Efficient 1-step radiolabeling of monoclonal antibodies to high specific activity with 225Ac for a-particle radioimmunotherapy of cancer Journal of Nuclear Medicine. 55: 1492-1498. PMID 24982438 DOI: 10.2967/jnumed.114.138347  1
2014 Veomett N, Dao T, Liu H, Xiang J, Pankov D, Dubrovsky L, Whitten JA, Park SM, Korontsvit T, Zakhaleva V, Casey E, Curcio M, Kharas MG, O'Reilly RJ, Liu C, ... Scheinberg DA, et al. Therapeutic efficacy of an Fc-enhanced TCR-like antibody to the intracellular WT1 oncoprotein. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 20: 4036-46. PMID 24850840 DOI: 10.1158/1078-0432.CCR-13-2756  1
2014 Dubrovsky L, Pankov D, Brea EJ, Dao T, Scott A, Yan S, O'Reilly RJ, Liu C, Scheinberg DA. A TCR-mimic antibody to WT1 bypasses tyrosine kinase inhibitor resistance in human BCR-ABL+ leukemias. Blood. 123: 3296-304. PMID 24723681 DOI: 10.1182/blood-2014-01-549022  1
2014 Sheth A, Escobar-Alvarez S, Gardner J, Ran L, Heaney ML, Scheinberg DA. Inhibition of human mitochondrial peptide deformylase causes apoptosis in c-myc-overexpressing hematopoietic cancers. Cell Death & Disease. 5: e1152. PMID 24675470 DOI: 10.1038/cddis.2014.112  1
2014 Justin Mulvey J, Feinberg EN, McDevitt MR, Scheinberg DA. Dialytic separation of bundled, Functionalized carbon nanotubes from carbonaceous impurities Crystals. 4: 450-465. DOI: 10.3390/cryst4040450  1
2013 Mulvey JJ, Villa CH, McDevitt MR, Escorcia FE, Casey E, Scheinberg DA. Self-assembly of carbon nanotubes and antibodies on tumours for targeted amplified delivery Nature Nanotechnology. 8: 763-771. PMID 24077028 DOI: 10.1038/nnano.2013.190  1
2013 Dao T, Liu C, Scheinberg DA. Approaching untargetable tumor-associated antigens with antibodies. Oncoimmunology. 2: e24678. PMID 24073363 DOI: 10.4161/onci.24678  1
2013 Veomett N, Dao T, Scheinberg DA. Therapeutic antibodies to intracellular targets in cancer therapy. Expert Opinion On Biological Therapy. 13: 1485-8. PMID 23991764 DOI: 10.1517/14712598.2013.833602  1
2013 Scheinberg DA, McDevitt MR, Dao T, Mulvey JJ, Feinberg E, Alidori S. Carbon nanotubes as vaccine scaffolds Advanced Drug Delivery Reviews. 65: 2016-2022. PMID 23899863 DOI: 10.1016/j.addr.2013.07.013  1
2013 Mallikaratchy P, Gardner J, Nordstrøm LU, Veomett NJ, McDevitt MR, Heaney ML, Scheinberg DA. A self-assembling short oligonucleotide duplex suitable for pretargeting. Nucleic Acid Therapeutics. 23: 289-99. PMID 23848521 DOI: 10.1089/nat.2013.0425  1
2013 Scheinberg DA, Dao T, Liu C. Reaching un-drugable intracellular targets with the long arm of antibodies. Oncotarget. 4: 647-8. PMID 23800785 DOI: 10.18632/oncotarget.1039  1
2013 Alidori S, Asqiriba K, Londero P, Bergkvist M, Leona M, Scheinberg DA, McDevitt MR. Deploying RNA and DNA with Functionalized Carbon Nanotubes. The Journal of Physical Chemistry. C, Nanomaterials and Interfaces. 117: 5982-5992. PMID 23626864 DOI: 10.1021/jp312416d  0.72
2013 Dao T, Yan S, Veomett N, Pankov D, Zhou L, Korontsvit T, Scott A, Whitten J, Maslak P, Casey E, Tan T, Liu H, Zakhaleva V, Curcio M, Doubrovina E, ... ... Scheinberg DA, et al. Targeting the intracellular WT1 oncogene product with a therapeutic human antibody. Science Translational Medicine. 5: 176ra33. PMID 23486779 DOI: 10.1126/scitranslmed.3005661  1
2013 Alidori S, Asqiriba K, Londero P, Bergkvist M, Leona M, Scheinberg DA, McDevitt MR. Deploying RNA and DNA with functionalized carbon nanotubes Journal of Physical Chemistry C. 117: 5982-5992. DOI: 10.1021/jp312416d  1
2012 Haro KJ, Sheth A, Scheinberg DA. Dysregulation of IRP1-mediated iron metabolism causes gamma ray-specific radioresistance in leukemia cells. Plos One. 7: e48841. PMID 23155415 DOI: 10.1371/journal.pone.0048841  1
2012 Haro KJ, Scott AC, Scheinberg DA. Mechanisms of resistance to high and low linear energy transfer radiation in myeloid leukemia cells. Blood. 120: 2087-97. PMID 22829630 DOI: 10.1182/blood-2012-01-404509  1
2012 Chau DM, Crump CJ, Villa JC, Scheinberg DA, Li YM. Familial Alzheimer disease presenilin-1 mutations alter the active site conformation of γ-secretase. The Journal of Biological Chemistry. 287: 17288-96. PMID 22461631 DOI: 10.1074/jbc.M111.300483  1
2012 Tseng HM, Shum D, Bhinder B, Escobar S, Veomett NJ, Tomkinson AE, Gin DY, Djaballah H, Scheinberg DA. A high-throughput scintillation proximity-based assay for human DNA ligase IV. Assay and Drug Development Technologies. 10: 235-49. PMID 22192310 DOI: 10.1089/adt.2011.0404  1
2011 Scheinberg DA, McDevitt MR. Actinium-225 in targeted alpha-particle therapeutic applications. Current Radiopharmaceuticals. 4: 306-20. PMID 22202153  1
2011 Brentjens RJ, Rivière I, Park JH, Davila ML, Wang X, Stefanski J, Taylor C, Yeh R, Bartido S, Borquez-Ojeda O, Olszewska M, Bernal Y, Pegram H, Przybylowski M, Hollyman D, ... ... Scheinberg D, et al. Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias. Blood. 118: 4817-28. PMID 21849486 DOI: 10.1182/blood-2011-04-348540  1
2011 Carrasquillo JA, Pandit-Taskar N, O'Donoghue JA, Humm JL, Zanzonico P, Smith-Jones PM, Divgi CR, Pryma DA, Ruan S, Kemeny NE, Fong Y, Wong D, Jaggi JS, Scheinberg DA, Gonen M, et al. (124)I-huA33 antibody PET of colorectal cancer. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. 52: 1173-80. PMID 21764796 DOI: 10.2967/jnumed.110.086165  1
2011 Antczak C, Shum D, Bassit B, Frattini MG, Li Y, de Stanchina E, Scheinberg DA, Djaballah H. Identification of benzofuran-4,5-diones as novel and selective non-hydroxamic acid, non-peptidomimetic based inhibitors of human peptide deformylase. Bioorganic & Medicinal Chemistry Letters. 21: 4528-32. PMID 21719286 DOI: 10.1016/j.bmcl.2011.05.129  1
2011 Villa CH, Dao T, Ahearn I, Fehrenbacher N, Casey E, Rey DA, Korontsvit T, Zakhaleva V, Batt CA, Philips MR, Scheinberg DA. Single-walled carbon nanotubes deliver peptide antigen into dendritic cells and enhance IgG responses to tumor-associated antigens. Acs Nano. 5: 5300-11. PMID 21682329 DOI: 10.1021/nn200182x  1
2011 Seideman JH, Stancevic B, Rotolo JA, McDevitt MR, Howell RW, Kolesnick RN, Scheinberg DA. Alpha particles induce apoptosis through the sphingomyelin pathway. Radiation Research. 176: 434-46. PMID 21631289 DOI: 10.1667/RR2472.1  1
2011 Grimm J, Scheinberg DA. Will nanotechnology influence targeted cancer therapy? Seminars in Radiation Oncology. 21: 80-7. PMID 21356476 DOI: 10.1016/j.semradonc.2010.10.003  1
2011 Schwartz J, Jaggi JS, O'Donoghue JA, Ruan S, McDevitt M, Larson SM, Scheinberg DA, Humm JL. Renal uptake of bismuth-213 and its contribution to kidney radiation dose following administration of actinium-225-labeled antibody. Physics in Medicine and Biology. 56: 721-33. PMID 21220845 DOI: 10.1088/0031-9155/56/3/012  1
2011 Mallikaratchy PR, Ruggiero A, Gardner JR, Kuryavyi V, Maguire WF, Heaney ML, McDevitt MR, Patel DJ, Scheinberg DA. A multivalent DNA aptamer specific for the B-cell receptor on human lymphoma and leukemia. Nucleic Acids Research. 39: 2458-69. PMID 21030439 DOI: 10.1093/nar/gkq996  1
2011 Scheinberg DA, Villa CH, Escorcia F, Mcdevitt MR. Carbon Nanotubes Drug Delivery in Oncology: From Basic Research to Cancer Therapy. 2: 1163-1185. DOI: 10.1002/9783527634057.ch36  1
2010 Escorcia FE, Henke E, McDevitt MR, Villa CH, Smith-Jones P, Blasberg RG, Benezra R, Scheinberg DA. Selective killing of tumor neovasculature paradoxically improves chemotherapy delivery to tumors. Cancer Research. 70: 9277-86. PMID 21045141 DOI: 10.1158/0008-5472.CAN-10-2029  1
2010 Ruggiero A, Villa CH, Holland JP, Sprinkle SR, May C, Lewis JS, Scheinberg DA, McDevitt MR. Imaging and treating tumor vasculature with targeted radiolabeled carbon nanotubes. International Journal of Nanomedicine. 5: 783-802. PMID 21042424 DOI: 10.2147/IJN.S13300  1
2010 Rosenblat TL, McDevitt MR, Mulford DA, Pandit-Taskar N, Divgi CR, Panageas KS, Heaney ML, Chanel S, Morgenstern A, Sgouros G, Larson SM, Scheinberg DA, Jurcic JG. Sequential cytarabine and alpha-particle immunotherapy with bismuth-213-lintuzumab (HuM195) for acute myeloid leukemia. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 16: 5303-11. PMID 20858843 DOI: 10.1158/1078-0432.CCR-10-0382  1
2010 Escobar-Alvarez S, Gardner J, Sheth A, Manfredi G, Yang G, Ouerfelli O, Heaney ML, Scheinberg DA. Inhibition of human peptide deformylase disrupts mitochondrial function. Molecular and Cellular Biology. 30: 5099-109. PMID 20805355 DOI: 10.1128/MCB.00469-10  1
2010 Seideman JH, Shum D, Djaballah H, Scheinberg DA. A high-throughput screen for alpha particle radiation protectants. Assay and Drug Development Technologies. 8: 602-14. PMID 20658946 DOI: 10.1089/adt.2010.0291  1
2010 Ruggiero A, Villa CH, Bander E, Rey DA, Bergkvist M, Batt CA, Manova-Todorova K, Deen WM, Scheinberg DA, McDevitt MR. Paradoxical glomerular filtration of carbon nanotubes. Proceedings of the National Academy of Sciences of the United States of America. 107: 12369-74. PMID 20566862 DOI: 10.1073/pnas.0913667107  1
2010 O'Reilly RJ, Dao T, Koehne G, Scheinberg D, Doubrovina E. Adoptive transfer of unselected or leukemia-reactive T-cells in the treatment of relapse following allogeneic hematopoietic cell transplantation. Seminars in Immunology. 22: 162-72. PMID 20537908 DOI: 10.1016/j.smim.2010.02.003  0.48
2010 Krug LM, Dao T, Brown AB, Maslak P, Travis W, Bekele S, Korontsvit T, Zakhaleva V, Wolchok J, Yuan J, Li H, Tyson L, Scheinberg DA. WT1 peptide vaccinations induce CD4 and CD8 T cell immune responses in patients with mesothelioma and non-small cell lung cancer. Cancer Immunology, Immunotherapy : Cii. 59: 1467-79. PMID 20532500 DOI: 10.1007/s00262-010-0871-8  1
2010 Penack O, Henke E, Suh D, King CG, Smith OM, Na IK, Holland AM, Ghosh A, Lu SX, Jenq RR, Liu C, Murphy GF, Lu TT, May C, Scheinberg DA, et al. Inhibition of neovascularization to simultaneously ameliorate graft-vs-host disease and decrease tumor growth. Journal of the National Cancer Institute. 102: 894-908. PMID 20463307 DOI: 10.1093/jnci/djq172  1
2010 Maslak PG, Dao T, Krug LM, Chanel S, Korontsvit T, Zakhaleva V, Zhang R, Wolchok JD, Yuan J, Pinilla-Ibarz J, Berman E, Weiss M, Jurcic J, Frattini MG, Scheinberg DA. Vaccination with synthetic analog peptides derived from WT1 oncoprotein induces T-cell responses in patients with complete remission from acute myeloid leukemia. Blood. 116: 171-9. PMID 20400682 DOI: 10.1182/blood-2009-10-250993  1
2010 Scheinberg DA, Villa CH, Escorcia FE, McDevitt MR. Conscripts of the infinite armada: systemic cancer therapy using nanomaterials. Nature Reviews. Clinical Oncology. 7: 266-76. PMID 20351700 DOI: 10.1038/nrclinonc.2010.38  1
2010 Sofou S, Enmon R, Palm S, Kappel B, Zanzonico P, McDevitt MR, Scheinberg DA, Sgouros G. Large anti-HER2/neu liposomes for potential targeted intraperitoneal therapy of micrometastatic cancer. Journal of Liposome Research. 20: 330-40. PMID 20070139 DOI: 10.3109/08982100903544185  1
2009 Dao T, Korontsvit T, Zakhaleva V, Haro K, Packin J, Scheinberg DA. Identification of a human cyclin D1-derived peptide that induces human cytotoxic CD4 T cells. Plos One. 4: e6730. PMID 19707583 DOI: 10.1371/journal.pone.0006730  1
2009 Jain N, Reuben JM, Kantarjian H, Li C, Gao H, Lee BN, Cohen EN, Ebarb T, Scheinberg DA, Cortes J. Synthetic tumor-specific breakpoint peptide vaccine in patients with chronic myeloid leukemia and minimal residual disease: a phase 2 trial. Cancer. 115: 3924-34. PMID 19536894 DOI: 10.1002/cncr.24468  1
2009 Escobar-Alvarez S, Goldgur Y, Yang G, Ouerfelli O, Li Y, Scheinberg DA. Structure and activity of human mitochondrial peptide deformylase, a novel cancer target. Journal of Molecular Biology. 387: 1211-28. PMID 19236878 DOI: 10.1016/j.jmb.2009.02.032  1
2009 Senter PD, Scheinberg DA. Meeting report: drug carriers in medicine and biology. Molecular Pharmaceutics. 6: 82-5. PMID 19125609 DOI: 10.1021/mp800258g  1
2009 Lamanna N, Jurcic JG, Noy A, Maslak P, Gencarelli AN, Panageas KS, Heaney ML, Brentjens RJ, Golde DW, Scheinberg DA, Zelenetz AD, Weiss MA. Sequential therapy with fludarabine, high-dose cyclophosphamide, and rituximab in previously untreated patients with chronic lymphocytic leukemia produces high-quality responses: Molecular remissions predict for durable complete responses Journal of Clinical Oncology. 27: 491-497. PMID 19075280 DOI: 10.1200/JCO.2008.16.4459  1
2008 Villa CH, McDevitt MR, Escorcia FE, Rey DA, Bergkvist M, Batt CA, Scheinberg DA. Synthesis and biodistribution of oligonucleotide-functionalized, tumor-targetable carbon nanotubes. Nano Letters. 8: 4221-8. PMID 19367842 DOI: 10.1021/nl801878d  1
2008 Gómez-Nuñez M, Haro KJ, Dao T, Chau D, Won A, Escobar-Alvarez S, Zakhaleva V, Korontsvit T, Gin DY, Scheinberg DA. Non-natural and photo-reactive amino acids as biochemical probes of immune function. Plos One. 3: e3938. PMID 19079589 DOI: 10.1371/journal.pone.0003938  1
2008 Heaney ML, Gardner JR, Karasavvas N, Golde DW, Scheinberg DA, Smith EA, O'Connor OA. Vitamin C antagonizes the cytotoxic effects of antineoplastic drugs Cancer Research. 68: 8031-8038. PMID 18829561 DOI: 10.1158/0008-5472.CAN-08-1490  1
2008 Dudkin VY, Miller JS, Dudkina AS, Antczak C, Scheinberg DA, Danishefsky SJ. Toward a prostate specific antigen-based prostate cancer diagnostic assay: preparation of keyhole limpet hemocyanin-conjugated normal and transformed prostate specific antigen fragments. Journal of the American Chemical Society. 130: 13598-607. PMID 18798614 DOI: 10.1021/ja8028137  1
2008 Dao T, Scheinberg DA. Peptide vaccines for myeloid leukaemias. Best Practice & Research. Clinical Haematology. 21: 391-404. PMID 18790445 DOI: 10.1016/j.beha.2008.05.001  1
2008 Miederer M, Scheinberg DA, McDevitt MR. Realizing the potential of the Actinium-225 radionuclide generator in targeted alpha particle therapy applications. Advanced Drug Delivery Reviews. 60: 1371-82. PMID 18514364 DOI: 10.1016/j.addr.2008.04.009  1
2008 Maslak PG, Dao T, Gomez M, Chanel S, Packin J, Korontsvit T, Zakhaleva V, Pinilla-Ibarz J, Berman E, Scheinberg DA. A pilot vaccination trial of synthetic analog peptides derived from the BCR-ABL breakpoints in CML patients with minimal disease Leukemia. 22: 1613-1616. PMID 18256684 DOI: 10.1038/leu.2008.7  1
2007 Escorcia FE, McDevitt MR, Villa CH, Scheinberg DA. Targeted nanomaterials for radiotherapy. Nanomedicine (London, England). 2: 805-15. PMID 18095847 DOI: 10.2217/17435889.2.6.805  1
2007 Sofou S, Kappel BJ, Jaggi JS, McDevitt MR, Scheinberg DA, Sgouros G. Enhanced retention of the α-particle-emitting daughters of actinium-225 by liposome carriers Bioconjugate Chemistry. 18: 2061-2067. PMID 17935286 DOI: 10.1021/bc070075t  1
2007 McDevitt MR, Chattopadhyay D, Jaggi JS, Finn RD, Zanzonico PB, Villa C, Rey D, Mendenhall J, Batt CA, Njardarson JT, Scheinberg DA. PET imaging of soluble yttrium-86-labeled carbon nanotubes in mice. Plos One. 2: e907. PMID 17878942 DOI: 10.1371/journal.pone.0000907  1
2007 Jaggi JS, Carrasquillo JA, Seshan SV, Zanzonico P, Henke E, Nagel A, Schwartz J, Beattie B, Kappel BJ, Chattopadhyay D, Xiao J, Sgouros G, Larson SM, Scheinberg DA. Improved tumor imaging and therapy via i.v. IgG-mediated time-sequential modulation of neonatal Fc receptor. The Journal of Clinical Investigation. 117: 2422-30. PMID 17717602 DOI: 10.1172/JCI32226C1  1
2007 May RJ, Dao T, Pinilla-Ibarz J, Korontsvit T, Zakhaleva V, Zhang RH, Maslak P, Scheinberg DA. Peptide epitopes from the Wilms' tumor 1 oncoprotein stimulate CD4+ and CD8+ T cells that recognize and kill human malignant mesothelioma tumor cells. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 13: 4547-55. PMID 17671141 DOI: 10.1158/1078-0432.CCR-07-0708  1
2007 McDevitt MR, Chattopadhyay D, Kappel BJ, Jaggi JS, Schiffman SR, Antczak C, Njardarson JT, Brentjens R, Scheinberg DA. Tumor targeting with antibody-functionalized, radiolabeled carbon nanotubes. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. 48: 1180-9. PMID 17607040 DOI: 10.2967/jnumed.106.039131  1
2007 Nolan DJ, Ciarrocchi A, Mellick AS, Jaggi JS, Bambino K, Gupta S, Heikamp E, McDevitt MR, Scheinberg DA, Benezra R, Mittal V. Bone marrow-derived endothelial progenitor cells are a major determinant of nascent tumor neovascularization. Genes & Development. 21: 1546-58. PMID 17575055 DOI: 10.1101/gad.436307  1
2007 Antczak C, Shum D, Escobar S, Bassit B, Kim E, Seshan VE, Wu N, Yang G, Ouerfelli O, Li YM, Scheinberg DA, Djaballah H. High-throughput identification of inhibitors of human mitochondrial peptide deformylase. Journal of Biomolecular Screening. 12: 521-35. PMID 17435169 DOI: 10.1177/1087057107300463  1
2007 Singh Jaggi J, Henke E, Seshan SV, Kappel BJ, Chattopadhyay D, May C, McDevitt MR, Nolan D, Mittal V, Benezra R, Scheinberg DA. Selective alpha-particle mediated depletion of tumor vasculature with vascular normalization Plos One. 2. PMID 17342201 DOI: 10.1371/journal.pone.0000267  1
2007 Maslak PG, Jurcic JG, Scheinberg DA. Monoclonal antibody therapy of APL Current Topics in Microbiology and Immunology. 313: 205-219. PMID 17217045  1
2007 Ise T, Nagata S, Kreitman RJ, Wilson WH, Wayne AS, Stetler-Stevenson M, Bishop MR, Scheinberg DA, Rassenti L, Kipps TJ, Kyle RA, Jelinek DF, Pastan I. Elevation of soluble CD307 (IRTA2/FcRH5) protein in the blood and expression on malignant cells of patients with multiple myeloma, chronic lymphocytic leukemia, and mantle cell lymphoma. Leukemia. 21: 169-74. PMID 17051241 DOI: 10.1038/sj.leu.2404445  1
2006 Antczak C, Jaggi JS, LeFave CV, Curcio MJ, McDevitt MR, Scheinberg DA. Influence of the linker on the biodistribution and catabolism of actinium-225 self-immolative tumor-targeted isotope generators. Bioconjugate Chemistry. 17: 1551-60. PMID 17105236 DOI: 10.1021/bc060156+  1
2006 Pinilla-Ibarz J, May RJ, Korontsvit T, Gomez M, Kappel B, Zakhaleva V, Zhang RH, Scheinberg DA. Improved human T-cell responses against synthetic HLA-0201 analog peptides derived from the WT1 oncoprotein Leukemia. 20: 2025-2033. PMID 16990779 DOI: 10.1038/sj.leu.2404380  1
2006 Scheinberg DA, Jurcic JG, Maslak P. Antibody-drug conjugates in acute myeloid leukemia. Nature Clinical Practice. Oncology. 3: 238-9. PMID 16682998 DOI: 10.1038/ncponc0478  1
2006 Gomez-Nunez M, Pinilla-Ibarz J, Dao T, May RJ, Pao M, Jaggi JS, Scheinberg DA. Peptide binding motif predictive algorithms correspond with experimental binding of leukemia vaccine candidate peptides to HLA-A*0201 molecules Leukemia Research. 30: 1293-1298. PMID 16533527 DOI: 10.1016/j.leukres.2006.02.010  1
2006 Lamanna N, Kalaycio M, Maslak P, Jurcic JG, Heaney M, Brentjens R, Zelenetz AD, Horgan D, Gencarelli A, Panageas KS, Scheinberg DA, Weiss MA. Pentostatin, cyclophosphamide, and rituximab is an active, well-tolerated regimen for patients with previously treated chronic lymphocytic leukemia. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 24: 1575-81. PMID 16520464 DOI: 10.1200/JCO.2005.04.3836  1
2006 Jaggi JS, Seshan SV, McDevitt MR, Sgouros G, Hyjek E, Scheinberg DA. Mitigation of radiation nephropathy after internal alpha-particle irradiation of kidneys. International Journal of Radiation Oncology, Biology, Physics. 64: 1503-12. PMID 16503385 DOI: 10.1016/j.ijrobp.2005.11.036  1
2006 Bonavia AS, McDevitt MR, Curcio MJ, Scheinberg DA. Immunoreactivity assay for alpha-particle emitting monoclonal antibody constructs. Applied Radiation and Isotopes : Including Data, Instrumentation and Methods For Use in Agriculture, Industry and Medicine. 64: 470-4. PMID 16352433 DOI: 10.1016/j.apradiso.2005.11.004  1
2006 Kappel BJ, Pinilla-Ibarz J, Kochman AA, Eng JM, Hubbard VM, Leiner I, Pamer EG, Heller G, van den Brink MR, Scheinberg DA. Remodeling specific immunity by use of MHC tetramers: demonstration in a graft-versus-host disease model. Blood. 107: 2045-51. PMID 16269613 DOI: 10.1182/blood-2005-07-2828  1
2005 Dao T, Gomez-Nunez M, Antczak C, Kappel B, Jaggi JS, Korontsvit T, Zakhaleva V, Scheinberg DA. Natural killer cells license dendritic cell cross-presentation of B lymphoma cell--associated antigens. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 11: 8763-72. PMID 16361564 DOI: 10.1158/1078-0432.CCR-05-0975  1
2005 Kotzerke J, Bunjes D, Scheinberg DA. Radioimmunoconjugates in acute leukemia treatment: The future is radiant Bone Marrow Transplantation. 36: 1021-1026. PMID 16247432 DOI: 10.1038/sj.bmt.1705182  1
2005 Pinilla-Ibarz J, Korontsvit T, Zakhaleva V, Roberts W, Scheinberg DA. Synthetic peptide analogs derived from bcr/abl fusion proteins and the induction of heteroclitic human T-cell responses. Haematologica. 90: 1324-32. PMID 16219568  1
2005 Scheinberg DA. Immune surveillance of leukemia? Haematologica. 90: 1297B. PMID 16219552  1
2005 Jaggi JS, Seshan SV, McDevitt MR, LaPerle K, Sgouros G, Scheinberg DA. Renal tubulointerstitial changes after internal irradiation with alpha-particle-emitting actinium daughters. Journal of the American Society of Nephrology : Jasn. 16: 2677-89. PMID 15987754 DOI: 10.1681/ASN.2004110945  1
2005 Jaggi JS, Kappel BJ, McDevitt MR, Sgouros G, Flombaum CD, Cabassa C, Scheinberg DA. Efforts to control the errant products of a targeted in vivo generator. Cancer Research. 65: 4888-95. PMID 15930310 DOI: 10.1158/0008-5472.CAN-04-3096  1
2005 Gale RP, Horowitz MM, Talpaz M, Scheinberg DA, Molldrem J, Li Z, Baccarani M, Goldman JM, Tura S. Immune therapy of chronic myelogenous leukemia. Leukemia Research. 29: 583-6. PMID 15755511 DOI: 10.1016/j.leukres.2004.11.005  1
2005 Palomba ML, Roberts WK, Dao T, Manukian G, Guevara-Patiño JA, Wolchok JD, Scheinberg DA, Houghton AN. CD8+ T-cell-dependent immunity following xenogeneic DNA immunization against CD20 in a tumor challenge model of B-cell lymphoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 11: 370-9. PMID 15671568  1
2005 Mulford DA, Scheinberg DA, Jurcic JG. The promise of targeted {alpha}-particle therapy. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. 46: 199S-204S. PMID 15653670  1
2004 Caligiuri MA, Velardi A, Scheinberg DA, Borrello IM. Immunotherapeutic approaches for hematologic malignancies. Hematology / the Education Program of the American Society of Hematology. American Society of Hematology. Education Program. 337-53. PMID 15561691 DOI: 10.1182/asheducation-2004.1.337  1
2004 Miederer M, McDevitt MR, Borchardt P, Bergman I, Kramer K, Cheung NK, Scheinberg DA. Treatment of neuroblastoma meningeal carcinomatosis with intrathecal application of alpha-emitting atomic nanogenerators targeting disialo-ganglioside GD2. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 10: 6985-92. PMID 15501978 DOI: 10.1158/1078-0432.CCR-04-0859  1
2004 Lee MD, She Y, Soskis MJ, Borella CP, Gardner JR, Hayes PA, Dy BM, Heaney ML, Philips MR, Bornmann WG, Sirotnak FM, Scheinberg DA. Human mitochondrial peptide deformylase, a new anticancer target of actinonin-based antibiotics. The Journal of Clinical Investigation. 114: 1107-16. PMID 15489958 DOI: 10.1172/JCI22269  1
2004 Ballangrud AM, Yang WH, Palm S, Enmon R, Borchardt PE, Pellegrini VA, McDevitt MR, Scheinberg DA, Sgouros G. Alpha-particle emitting atomic generator (Actinium-225)-labeled trastuzumab (herceptin) targeting of breast cancer spheroids: efficacy versus HER2/neu expression. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 10: 4489-97. PMID 15240541 DOI: 10.1158/1078-0432.CCR-03-0800  1
2004 Yuan RR, Wong P, McDevitt MR, Doubrovina E, Leiner I, Bornmann W, O'reilly R, Pamer EG, Scheinberg DA. Targeted deletion of T-cell clones using alpha-emitting suicide MHC tetramers. Blood. 104: 2397-402. PMID 15217835 DOI: 10.1182/blood-2004-01-0324  1
2004 Moldenhauer A, Frank RC, Pinilla-Ibarz J, Holland G, Boccuni P, Scheinberg DA, Salama A, Seeger K, Moore MA, Nimer SD. Histone deacetylase inhibition improves dendritic cell differentiation of leukemic blasts with AML1-containing fusion proteins. Journal of Leukocyte Biology. 76: 623-33. PMID 15197237 DOI: 10.1189/jlb.1103581  1
2004 Crowley WF, Sherwood L, Salber P, Scheinberg D, Slavkin H, Tilson H, Reece EA, Catanese V, Johnson SB, Dobs A, Genel M, Korn A, Reame N, Bonow R, Grebb J, et al. Clinical research in the United States at a crossroads: proposal for a novel public-private partnership to establish a national clinical research enterprise. Jama. 291: 1120-6. PMID 14996782 DOI: 10.1001/jama.291.9.1120  1
2004 Sofou S, Thomas JL, Lin HY, McDevitt MR, Scheinberg DA, Sgouros G. Engineered liposomes for potential alpha-particle therapy of metastatic cancer. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. 45: 253-60. PMID 14960644  1
2004 Miederer M, McDevitt MR, Sgouros G, Kramer K, Cheung NK, Scheinberg DA. Pharmacokinetics, dosimetry, and toxicity of the targetable atomic generator, 225Ac-HuM195, in nonhuman primates. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. 45: 129-37. PMID 14734685  1
2004 Cathcart K, Pinilla-Ibarz J, Korontsvit T, Schwartz J, Zakhaleva V, Papadopoulos EB, Scheinberg DA. A multivalent bcr-abl fusion peptide vaccination trial in patients with chronic myeloid leukemia. Blood. 103: 1037-42. PMID 14504104 DOI: 10.1182/blood-2003-03-0954  1
2003 Lee MD, Antczak C, Li Y, Sirotnak FM, Bornmann WG, Scheinberg DA. A new human peptide deformylase inhibitable by actinonin. Biochemical and Biophysical Research Communications. 312: 309-15. PMID 14637138 DOI: 10.1016/j.bbrc.2003.10.123  1
2003 Burke JM, Caron PC, Papadopoulos EB, Divgi CR, Sgouros G, Panageas KS, Finn RD, Larson SM, O'Reilly RJ, Scheinberg DA, Jurcic JG. Cytoreduction with iodine-131-anti-CD33 antibodies before bone marrow transplantation for advanced myeloid leukemias Bone Marrow Transplantation. 32: 549-556. PMID 12953125 DOI: 10.1038/sj.bmt.1704201  1
2003 Borchardt PE, Yuan RR, Miederer M, McDevitt MR, Scheinberg DA. Targeted actinium-225 in vivo generators for therapy of ovarian cancer. Cancer Research. 63: 5084-90. PMID 12941838  1
2003 Weiss MA, Maslak PG, Jurcic JG, Scheinberg DA, Aliff TB, Lamanna N, Frankel SR, Kossman SE, Horgan D. Pentostatin and cyclophosphamide: an effective new regimen in previously treated patients with chronic lymphocytic leukemia. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 21: 1278-84. PMID 12663715 DOI: 10.1200/JCO.2003.08.100  1
2003 Sung NS, Crowley WF, Genel M, Salber P, Sandy L, Sherwood LM, Johnson SB, Catanese V, Tilson H, Getz K, Larson EL, Scheinberg D, Reece EA, Slavkin H, Dobs A, et al. Central challenges facing the national clinical research enterprise. Jama. 289: 1278-87. PMID 12633190 DOI: 10.1001/jama.289.10.1278  1
2003 Schwartz J, Pinilla-Ibarz J, Yuan RR, Scheinberg DA. Novel targeted and immunotherapeutic strategies in chronic myeloid leukemia. Seminars in Hematology. 40: 87-96. PMID 12563615 DOI: 10.1053/shem.2003.50007  1
2003 McGrath MS, Rosenblum MG, Philips MR, Scheinberg DA. Immunotoxin resistance in multidrug resistant cells. Cancer Research. 63: 72-9. PMID 12517780  1
2002 McDevitt MR, Ma D, Simon J, Frank RK, Scheinberg DA. Design and synthesis of 225Ac radioimmunopharmaceuticals. Applied Radiation and Isotopes : Including Data, Instrumentation and Methods For Use in Agriculture, Industry and Medicine. 57: 841-7. PMID 12406626 DOI: 10.1016/S0969-8043(02)00167-7  1
2002 Weiss MA, Aliff TB, Tallman MS, Frankel SR, Kalaycio ME, Maslak PG, Jurcic JG, Scheinberg DA, Roma TE. A single, high dose of idarubicin combined with cytarabine as induction therapy for adult patients with recurrent or refractory acute lymphoblastic leukemia. Cancer. 95: 581-7. PMID 12209751 DOI: 10.1002/cncr.10707  1
2002 Jurcic JG, Larson SM, Sgouros G, McDevitt MR, Finn RD, Divgi CR, Ballangrud AM, Hamacher KA, Ma D, Humm JL, Brechbiel MW, Molinet R, Scheinberg DA. Targeted alpha particle immunotherapy for myeloid leukemia. Blood. 100: 1233-9. PMID 12149203  0.72
2002 McDevitt MR, Scheinberg DA. Ac-225 and her daughters: The many faces of Shiva Cell Death and Differentiation. 9: 593-594. PMID 12032666 DOI: 10.1038/sj/cdd/4401047  1
2002 Roberts WK, Livingston PO, Agus DB, Pinilla-Ibarz J, Zelenetz A, Scheinberg DA. Vaccination with CD20 peptides induces a biologically active, specific immune response in mice. Blood. 99: 3748-55. PMID 11986232 DOI: 10.1182/blood.V99.10.3748  1
2002 Burke JM, Jurcic JG, Scheinberg DA. Radioimmunotherapy for acute leukemia. Cancer Control : Journal of the Moffitt Cancer Center. 9: 106-13. PMID 11965231  1
2002 Ma D, McDevitt MR, Barendswaard E, Lai L, Curcio MJ, Pellegrini V, Brechbiel MW, Scheinberg DA. Radioimmunotherapy for model B cell malignancies using 90Y-labeled anti-CD19 and anti-CD20 monoclonal antibodies Leukemia. 16: 60-66. PMID 11840264 DOI: 10.1038/sj/leu/2402320  1
2001 Jurcic JG, Nimer SD, Scheinberg DA, DeBlasio T, Warrell RP, Miller WH. Prognostic significance of minimal residual disease detection and PML/RAR-alpha isoform type: long-term follow-up in acute promyelocytic leukemia. Blood. 98: 2651-6. PMID 11675334 DOI: 10.1182/blood.V98.9.2651  1
2001 Ma D, McDevitt MR, Finn RD, Scheinberg DA. Breakthrough of 225Ac and its radionuclide daughters from an 225Ac/213Bi generator: Development of new methods, quantitative characterization, and implications for clinical use Applied Radiation and Isotopes. 55: 667-678. PMID 11573800 DOI: 10.1016/S0969-8043(01)00062-8  1
2001 Ma D, McDevitt MR, Finn RD, Scheinberg DA. Rapid preparation of short-lived alpha particle emitting radioimmunopharmaceuticals Applied Radiation and Isotopes. 55: 463-470. PMID 11545498 DOI: 10.1016/S0969-8043(01)00048-3  1
2001 Ballangrud AM, Yang WH, Charlton DE, McDevitt MR, Hamacher KA, Panageas KS, Ma D, Bander NH, Scheinberg DA, Sgouros G. Response of LNCaP spheroids after treatment with an α-particle emitter (213Bi)-labeled anti-prostate-specific membrane antigen antibody (J591) Cancer Research. 61: 2008-2014. PMID 11280760  1
2001 Kolbert KS, Hamacher KA, Jurcic JG, Scheinberg DA, Larson SM, Sgouros G. Parametric images of antibody pharmacokinetics in Bi213-HuM195 therapy of leukemia Journal of Nuclear Medicine. 42: 27-32. PMID 11197975  1
2000 Frankel AE, Sievers EL, Scheinberg DA. Cell surface receptor-targeted therapy of acute myeloid leukemia: A review Cancer Biotherapy and Radiopharmaceuticals. 15: 459-476. PMID 11155818  1
2000 Scheinberg DA. Old, new drugs and new, new drugs for the new millennium Current Oncology Reports. 2: 112-113. PMID 11122831  1
2000 Scheinberg DA. Speed bumps on the road to antibody therapy Cancer Journal. 6: 64-65. PMID 11069220  1
2000 Pinilla-Ibarz J, Cathcart K, Scheinberg DA. CML vaccines as a paradigm of the specific immunotherapy of cancer Blood Reviews. 14: 111-120. PMID 11012250 DOI: 10.1054/blre.2000.0127  1
2000 Weiss MA, Glenn M, Maslak P, Rahman Z, Noy A, Zelenetz A, Scheinberg DA, Golde DW. Consolidation therapy with high-dose cyclophosphamide improves the quality of response in patients with chronic lymphocytic leukemia treated with fludarabine as induction therapy Leukemia. 14: 1577-1582. PMID 10995003  1
2000 Camacho LH, Soignet SL, Chanel S, Ho R, Heller G, Scheinberg DA, Ellison R, Warrell RP. Leukocytosis and the retinoic acid syndrome in patients with acute promyelocytic leukemia treated with arsenic trioxide Journal of Clinical Oncology. 18: 2620-2625. PMID 10893295  1
2000 Jurcic JG, Cathcart K, Pinilla-Ibarz J, Scheinberg DA. Advances in immunotherapy of hematologic malignancies: Cellular and humoral approaches Current Opinion in Hematology. 7: 247-254. PMID 10882181 DOI: 10.1097/00062752-200007000-00008  1
2000 Houghton AN, Scheinberg DA. Monoclonal antibody therapies - A 'constant' threat to cancer Nature Medicine. 6: 373-374. PMID 10742135 DOI: 10.1038/74621  1
2000 Jurcic JG, DeBlasio T, Dumont L, Yao TJ, Scheinberg DA. Molecular remission induction with retinoic acid and anti-CD33 monoclonal antibody HuM195 in acute promyelocytic leukemia Clinical Cancer Research. 6: 372-380. PMID 10690513  1
2000 Bocchia M, Marconcini S, Birtolo S, Raspadori D, Bucalossi A, Amabile M, Scheinberg DA, Lauria F. Vaccination of CML patients with a P210-derived peptide vaccine plus QS-21 and GM-CSF Blood. 96.  1
1999 Sgouros G, Ballangrud AM, Jurcic JG, McDevitt MR, Humm JL, Erdi YE, Mehta BM, Finn RD, Larson SM, Scheinberg DA. Pharmacokinetics and dosimetry of an α-particle emitter labeled antibody: 213Bi-HuM195 (anti-CD33) in patients with leukemia Journal of Nuclear Medicine. 40: 1935-1946. PMID 10565792  1
1999 Jurcic JG, Scheinberg DA. Radionuclides as conditioning before stem cell transplantation Current Opinion in Hematology. 6: 371-376. PMID 10546789 DOI: 10.1097/00062752-199911000-00003  1
1999 Kossman SE, Scheinberg DA, Jurcic JG, Jimenez J, Caron PC. A phase I trial of humanized monoclonal antibody HuM195 (anti-CD33) with low-dose interleukin 2 in acute myelogenous leukemia Clinical Cancer Research. 5: 2748-2755. PMID 10537338  1
1999 Hom JS, Goldberg I, Mathis J, Pan YX, Brooks AI, Ryan-Moro J, Scheinberg DA, Pasternak GW. [(125)I]orphanin FQ/nociceptin binding in Raji cells. Synapse (New York, N.Y.). 34: 187-91. PMID 10523756 DOI: 10.1002/(SICI)1098-2396(19991201)34:3<187::AID-SYN3>3.0.CO;2-A  1
1999 McDevitt MR, Finn RD, Ma D, Larson SM, Scheinberg DA. Preparation of α-emitting 213Bi-labeled antibody constructs for clinical use Journal of Nuclear Medicine. 40: 1722-1727. PMID 10520715  1
1999 McDevitt MR, Finn RD, Sgouros G, Ma D, Scheinberg DA. An 225Ac/213Bi generator system for therapeutic clinical applications: Construction and operation Applied Radiation and Isotopes. 50: 895-904. PMID 10214708 DOI: 10.1016/S0969-8043(98)00151-1  1
1999 Weisburg JH, Roepe PD, Dzekunov S, Scheinberg DA. Intracellular ph and multidrug resistance regulate complement-mediated cytotoxicity of nucleated human cells Journal of Biological Chemistry. 274: 10877-10888. PMID 10196165 DOI: 10.1074/jbc.274.16.10877  1
1999 Ma D, McDevitt MR, Finn RD, Scheinberg DA. An anion exchange purification method for bismuth-213 labeled monoclonal antibodies in application of radioimmunotherapy Journal of Labelled Compounds and Radiopharmaceuticals. 42.  1
1998 Soignet SL, Maslak P, Wang ZG, Jhanwar S, Calleja E, Dardashti LJ, Corso D, DeBlasio A, Gabrilove J, Scheinberg DA, Pandolfi PP, Warrell RP. Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide New England Journal of Medicine. 339: 1341-1348. PMID 9801394 DOI: 10.1056/NEJM199811053391901  1
1998 McDevitt MR, Sgouros G, Finn RD, Humm JL, Jurcic JG, Larson SM, Scheinberg DA. Radioimmunotherapy with alpha-emitting nuclides European Journal of Nuclear Medicine. 25: 1341-1351. PMID 9724387 DOI: 10.1007/s002590050306  1
1998 Pagliaro LC, Liu B, Munker R, Andreeff M, Freireich EJ, Scheinberg DA, Rosenblum MG. Humanized M195 monoclonal antibody conjugated to recombinant gelonin: An anti-CD33 immunotoxin with antileukemic activity Clinical Cancer Research. 4: 1971-1976. PMID 9717827  1
1998 Wang ZG, Rivi R, Delva L, König A, Scheinberg DA, Gambacorti-Passerini C, Gabrilove JL, Warrell RP, Pandolfi PP. Arsenic trioxide and melarsoprol induce programmed cell death in myeloid leukemia cell lines and function in a PML and PML-RARα independent manner Blood. 92: 1497-1504. PMID 9716575  1
1998 Caron PC, Dumont L, Scheinberg DA. Supersaturating infusional humanized anti-CD33 monoclonal antibody HuM195 in myelogenous leukemia Clinical Cancer Research. 4: 1421-1428. PMID 9626458  1
1998 Xu Y, Lai LT, Gabrilove JL, Scheinberg DA. Antitumor activity of actinonin in vitro and in vivo Clinical Cancer Research. 4: 171-176. PMID 9516967  1
1997 Caron PC, Scheinberg DA. The biological therapy of acute and chronic leukemia Cancer Investigation. 15: 342-352. PMID 9246157  1
1997 Bocchia M, Xu Q, Wesley U, Xu Y, Korontsvit T, Loganzo F, Albino AP, Scheinberg DA. Modulation of p53, WAF1/p21 and BCL-2 expression during retinoic acid-induced differentiation of NB4 promyelocytic cells Leukemia Research. 21: 439-447. PMID 9225073 DOI: 10.1016/S0145-2126(96)00085-9  1
1997 Xu Y, Wellner D, Scheinberg DA. Cryptic and regulatory epitopes in CD13/Aminopeptidase N Experimental Hematology. 25: 521-529. PMID 9197331  1
1997 Mathis JP, Ryan-Moro J, Chang A, Hom JS, Scheinberg DA, Pasternak GW. Biochemical evidence for orphanin FQ/nociceptin receptor heterogeneity in mouse brain. Biochemical and Biophysical Research Communications. 230: 462-5. PMID 9016803 DOI: 10.1006/bbrc.1996.5867  1
1996 Weiss M, Maslak P, Feldman E, Berman E, Bertino J, Gee T, Megherian L, Seiter K, Scheinberg D, Golde D. Cytarabine with high-dose mitoxantrone induces rapid complete remissions in adult acute lymphoblastic leukemia without the use of vincristine or prednisone Journal of Clinical Oncology. 14: 2480-2485. PMID 8823326  1
1996 O'Boyle KP, Freeman K, Kalisiak A, Agregado A, Scheinberg DA. Patterns of ganglioside expression in B cell neoplasms Leukemia and Lymphoma. 21: 255-266. PMID 8726407  1
1996 Sgouros G, Jureidini IM, Scott AM, Graham MC, Larson SM, Scheinberg DA. Bone Marrow Dosimetry: Regional Variability of Marrow-Localizing Antibody Journal of Nuclear Medicine. 37: 695-698. PMID 8691269  1
1996 Jakubowski A, Scheinberg DA. Noninvasive evaluation of the bone marrow Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. 37: 982-984. PMID 8683327  1
1996 Weisburg JH, Curcio M, Caron PC, Raghu G, Mechetner EB, Roepe PD, Scheinberg DA. The multidrug resistance phenotype confers immunological resistance Journal of Experimental Medicine. 183: 2699-2704. PMID 8676093 DOI: 10.1084/jem.183.6.2699  1
1996 Xu Y, Xu Q, Rosenblum MG, Scheinberg DA. Antileukemic activity of recombinant humanized M195-gelonin immunotoxin in nude mice Leukemia. 10: 321-326. PMID 8637241  1
1996 Bocchia M, Korontsvit T, Xu Q, Mackinnon S, Soo Young Yang, Sette A, Scheinberg DA. Specific human cellular immunity to bcr-abl oncogene-derived peptides Blood. 87: 3587-3592. PMID 8611681  1
1996 Maslak PG, Weiss MA, Berman E, Yao TJ, Tyson D, Golde DW, Scheinberg DA. Granulocyte colony-stimulating factor following chemotherapy in elderly patients with newly diagnosed acute myelogenous leukemia Leukemia. 10: 32-39. PMID 8558934  1
1996 Scheinberg DA. Passive and active specific immunotherapy of myeloid leukemias Experimental Hematology. 24: 1121.  1
1996 Hession MA, Groeger JS, Huang Y, Scheinberg DA. Predictors of outcome for leukemia patients in the intensive care unit Chest. 110.  1
1995 Jurcic JG, Scheinberg DA. Radioimmunotherapy of Hematological Cancer: Problems and Progress Clinical Cancer Research. 1: 1439-1446. PMID 9815942  1
1995 Xu Y, Scheinberg DA. Elimination of Human Leukemia by Monoclonal Antibodies in an Athymic Nude Mouse Leukemia Model Clinical Cancer Research. 1: 1179-1187. PMID 9815910  1
1995 Caron PC, Lai LT, Scheinberg DA. Interleukin-2 Enhancement of Cytotoxicity by Humanized Monoclonal Antibody M195 (Anti-CD33) in Myelogenous Leukemia Clinical Cancer Research. 1: 63-70. PMID 9815888  1
1995 Jurcic JC, Caron PC, Miller WH, Yao TJ, Maslak P, Finn RD, Larson SM, Warrell RP, Scheinberg DA. Sequential targeted therapy for relapsed acute promyelocytic leukemia with all-trans retinoic acid and anti-CD33 monoclonal antibody M195 Leukemia. 9: 244-248. PMID 7869759  1
1995 Bocchia M, Wentworth PA, Southwood S, Sidney J, McGraw K, Scheinberg DA, Sette A. Specific binding of leukemia oncogene fusion protein peptides to HLA class I molecules. Blood. 85: 2680-4. PMID 7742526  1
1995 Nikula TK, Curcio MJ, Brechbiel MW, Gansow OA, Finn RD, Scheinberg DA. A rapid, single vessel method for preparation of clinical grade ligand conjugated monoclonal antibodies. Nuclear Medicine and Biology. 22: 387-90. PMID 7627155 DOI: 10.1016/0969-8051(94)00126-5  1
1995 Nikula TK, Bocchia M, Curcio MJ, Sgouros G, Ma Y, Finn RD, Scheinberg DA. Impact of the high tyrosine fraction in complementarity determining regions: measured and predicted effects of radioiodination on IgG immunoreactivity Molecular Immunology. 32: 865-872. PMID 7565813 DOI: 10.1016/0161-5890(95)00052-G  1
1995 Minasian LM, Tzy Jyun Yao, Steffens TA, Scheinberg DA, Williams L, Riedel E, Houghton AN, Chapman PB. A phase I study of anti-GD3 ganglioside monoclonal antibody R24 and recombinant human macrophage-colony stimulating factor in patients with metastatic melanoma Cancer. 75: 2251-2257. PMID 7536122  1
1995 Xu Y, Wellner D, Scheinberg DA. Substance P and Bradykinin Are Natural Inhibitors of CD13/Aminopeptidase N Biochemical and Biophysical Research Communications. 208: 664-674. PMID 7535053 DOI: 10.1006/bbrc.1995.1390  1
1995 Jurcic JG, Caron PC, Scheinberg DA. Monoclonal antibody therapy of leukemia and lymphoma Advances in Pharmacology (San Diego, Calif.). 33: 287-314. PMID 7495673  1
1994 Caron PC, Schwartz MA, Man Sung Co, Queen C, Finn RD, Graham MC, Divgi CR, Larson SM, Scheinberg DA. Murine and humanized constructs of monoclonal antibody M195 (anti-CD33) for the therapy of acute myelogenous leukemia Cancer. 73: 1049-1056. PMID 8306247  1
1994 Caron PC, Scheinberg DA. Immunotherapy for acute leukemias Current Opinion in Oncology. 6: 14-22. PMID 8204688  1
1994 Caron PC, Jurcic JG, Scott AM, Finn RD, Divgi CR, Graham MC, Jureidini IM, Sgouros G, Tyson D, Old LJ, Larson SM, Scheinberg DA. A phase 1B trial of humanized monoclonal antibody M195 (anti-CD33) in myeloid leukemia: Specific targeting without immunogenicity Blood. 83: 1760-1768. PMID 8142644  1
1994 McGraw KJ, Rosenblum MG, Cheung L, Scheinberg DA. Characterization of murine and humanized anti-CD33, gelonin immunotoxins reactive against myeloid leukemias. Cancer Immunology, Immunotherapy : Cii. 39: 367-74. PMID 8001024 DOI: 10.1007/BF01534423  1
1994 Vahdat L, Maslak P, Miller WH, Eardley A, Heller G, Scheinberg DA, Warrell RP. Early mortality and the retinoic acid syndrome in acute promyelocytic leukemia: Impact of leukocytosis, low-dose chemotherapy, PMN/RAR-α isoform, and CD13 expression in patients treated with all-trans retinoic acid Blood. 84: 3843-3849. PMID 7949141  1
1994 Jurcic JG, Scheinberg DA. Recent developments in the radioimmunotherapy of cancer Current Opinion in Immunology. 6: 715-721. PMID 7826526 DOI: 10.1016/0952-7915(94)90074-4  1
1994 Jurcic JG, Scheinberg DA. Monoclonal antibody therapy of leukemia Antibody, Immunoconjugates, and Radiopharmaceuticals. 7: 203-223.  1
1993 Czuczman MS, Garin-Chesa P, Lemoli RM, Scheinberg DA. IgM monoclonal antibody JD118 recognizes an inducible antigen target for human-complement-mediated cytotoxicity against neoplastic B cells Cancer Immunology Immunotherapy. 36: 387-396. PMID 8500111 DOI: 10.1007/BF01742255  1
1993 Sgouros G, Graham MC, Divgi CR, Larson SM, Scheinberg DA. Modeling and dosimetry of monoclonal antibody M195 (anti-CD33) in acute myelogenous leukemia Journal of Nuclear Medicine. 34: 422-430. PMID 8441034  1
1993 Schwartz MA, Lovett DR, Redner A, Finn RD, Graham MC, Divgi CR, Dantis L, Gee TS, Andreeff M, Old LJ, Larson SM, Scheinberg DA. Dose-escalation trial of M195 labeled with iodine 131 for cytoreduction and marrow ablation in relapsed or refractory myeloid leukemias Journal of Clinical Oncology. 11: 294-303. PMID 8426207 DOI: 10.1200/JCO.1993.11.2.294  1
1993 Czuczman MS, Straus DJ, Divgi CR, Graham M, Garin-Chesa P, Finn R, Myers J, Old LJ, Larson SM, Scheinberg DA. Phase I dose-escalation trial of iodine 131-labeled monoclonal antibody OKB7 in patients with non-hodgkin's lymphoma Journal of Clinical Oncology. 11: 2021-2029. PMID 8410126  1
1993 Man Sung Co, Scheinberg DA, Avdalovic NM, Mcgraw K, Vasquez M, Caron PC, Queen C. Genetically engineered deglycosylation of the variable domain increases the affinity of an anti-CD33 monoclonal antibody Molecular Immunology. 30: 1361-1367. PMID 8232322 DOI: 10.1016/0161-5890(93)90097-U  1
1993 Caron PC, Scheinberg DA. Anti-CD33 monoclonal antibody m195 for the therapy of myeloid leukemia Leukemia and Lymphoma. 11: 1-6. PMID 8124221 DOI: 10.3109/10428199309064254  1
1993 Sgouros G, Scheinberg DA. Treatment of leukemia with radiolabeled monoclonal antibodies Cancer Treatment and Research. 68: 23-64. PMID 8105852  1
1993 Maslak P, Miller WH, Heller G, Scheinberg DA, Dmitrovsky E, Warrell RP. CD2 expression and PML/RAR-α transcripts in acute promyelocytic leukemia [2] Blood. 81: 1666. PMID 8095829  1
1993 Czuczman MS, Class K, Scheinberg DA. Interleukin-4 priming enhances a target for human complement-mediated cytotoxicity of CLL Leukemia. 7: 1020-1025. PMID 7686603  1
1993 Scheinberg DA. Monoclonal antibodies in the treatment of myelogenous leukemias Cancer Treatment and Research. 64: 213-232. PMID 7680876  1
1992 Co MS, Avdalovic NM, Caron PC, Avdalovic MV, Scheinberg DA, Queen C. Chimeric and humanized antibodies with specificity for the CD33 antigen Journal of Immunology. 148: 1149-1154. PMID 1737932  1
1992 Caron PC, Co MS, Bull MK, Avdalovic NM, Queen C, Scheinberg DA. Biological and immunological features of humanized M195 (anti-CD33) monoclonal antibodies. Cancer Research. 52: 6761-7. PMID 1458463  1
1992 Caron PC, Laird W, Co MS, Avdalovic NM, Queen C, Scheinberg DA. Engineered humanized dimeric forms of IgG are more effective antibodies Journal of Experimental Medicine. 176: 1191-1195. PMID 1402660  1
1992 Muindi J, Frankel SR, Miller WH, Jakubowski A, Scheinberg DA, Young CW, Dmitrovsky E, Warrell RP. Continuous treatment with all-trans retinoic acid causes a progressive reduction in plasma drug concentrations: implications for relapse and retinoid "resistance" in patients with acute promyelocytic leukemia. Blood. 79: 299-303. PMID 1309668  1
1991 Lemoli RM, Gasparetto C, Scheinberg DA, Moore MAS, Clarkson BD, Gulati SC. Autologous bone marrow transplantation in acute myelogenous leukemia: In vitro treatment with myeloid-specific monoclonal antibodies and drugs in combination Blood. 77: 1829-1836. PMID 2015406  1
1991 Scheinberg DA, Lovett D, Divgi CR, Graham MC, Berman E, Pentlow K, Feirt N, Finn RD, Clarkson BD, Gee TS, Larson SM, Oettgen HF. A phase I trial of monoclonal antibody M195 in acute myelogenous leukemia: Specific bone marrow targeting and internalization of radionuclide Journal of Clinical Oncology. 9: 478-490. PMID 1999719  1
1991 Kalisiak A, Minniti JG, Oosterwijk E, Old LJ, Scheinberg DA. Neutral glycosphingolipid expression in B-cell neoplasms International Journal of Cancer. 49: 837-845. PMID 1959988 DOI: 10.1002/ijc.2910490607  1
1991 Lovett DR, Scheinberg DA, Houghton AN. Monoclonal antibody therapy for cancer Cancer Chemotherapy and Biological Response Modifiers. 12: 147-163. PMID 1931442  1
1991 Oosterwijk E, Kalisiak A, Wakka JC, Scheinberg DA, Old LJ. Monoclonal antibodies against Galα1-4Galβ1-4Glc (P(k), CD77) produced with a synthetic glycoconjugate as immunogen: Reactivity with carbohydrates, with fresh frozen human tissues and hematopoietic tumors International Journal of Cancer. 48: 848-854. PMID 1860732  1
1991 Kalisiak A, Oosterwijk E, Minniti JG, Old LJ, Scheinberg DA. A monoclonal antibody for terminal β-galactose. Use in analysis of glycosphingolipids Glycoconjugate Journal. 8: 55-62. PMID 1726670 DOI: 10.1007/BF00731643  1
1991 Scheinberg DA, Bull MK, Yang SY, Class KA, Minniti JG. Inhibition of cell proliferation with an HLA-A-specific monoclonal antibody. Tissue Antigens. 38: 213-23. PMID 1723543  1
1991 Scheinberg DA. Current applications of monoclonal antibodies for the therapy of hematopoietic cancers Current Opinion in Immunology. 3: 679-684. PMID 1661602 DOI: 10.1016/0952-7915(91)90096-J  1
1991 Chapman PB, Scheinberg DA, DiMaggio JJ, Houghton AN. Unconjugated monoclonal antibodies as anticancer agents Immunology and Allergy Clinics of North America. 11: 257-275.  1
1990 Scheinberg DA, Straus DJ, Yeh SD, Divgi C, Garin-Chesa P, Graham M, Pentlow K, Coit D, Oettgen HF, Old LJ. A phase I toxicity, pharmacology, and dosimetry trial of monoclonal antibody OKB7 in patients with non-Hodgkin's lymphoma: Effects of tumor burden and antigen expression Journal of Clinical Oncology. 8: 792-803. PMID 2332769  1
1990 Scheinberg DA, Strand M. Radioimmunotherapy in experimental animal models: Principles derived from models Cancer Research. 50. PMID 2297749  1
1990 Yuasa H, Scheinberg DA, Houghton AN. Gangliosides of T lymphocytes: Evidence for a role in T-cell activation Tissue Antigens. 36: 47-56. PMID 2270542  1
1990 Shimazaki C, Fried J, Perez AG, Scheinberg DA, Atzpodien J, Wang CY, Wisniewolski R, Clarkson BD. Immunophenotypic analysis of lymphocytes and myeloma cells in patients with multiple myeloma. Acta Haematologica. 83: 123-9. PMID 2109450 DOI: 10.1159/000205187  1
1989 Scheinberg DA, Tanimoto M, McKenzie S, Strife A, Old LJ, Clarkson BD. Monoclonal antibody M195: A diagnostic marker for acute myelogenous leukemia Leukemia. 3: 440-445. PMID 2725060  1
1989 Tanimoto M, Scheinberg DA, Cordon-Cardo C, Huie D, Clarkson BD, Old LJ. Restricted expression of an early myeloid and monocytic cell surface antigen defined by monoclonal antibody M195 Leukemia. 3: 339-348. PMID 2716349  1
1989 Eton O, Scheinberg DA, Houghton AN. Establishment and characterization of two human myeloma cell lines secreting kappa light chains Leukemia. 3: 729-735. PMID 2506399  1
1988 Shimazaki C, Wisniewski D, Scheinberg DA, Atzpodien J, Strife A, Gulati S, Fried J, Wisniewolski R, Wang CY, Clarkson BD. Elimination of myeloma cells from bone marrow by using monoclonal antibodies and magnetic immunobeads Blood. 72: 1248-1254. PMID 3167207  1
1987 Scheinberg DA, Houghton AN. Current status of antitumor therapy with monoclonal antibodies Oncology (Williston Park, N.Y.). 1: 31-40. PMID 3079479  1
1986 Houghton AN, Scheinberg DA. Monoclonal antibodies: Potential applications to the treatment of cancer Seminars in Oncology. 13: 165-179. PMID 3520825  1
1983 Scheinberg DA, Pan XQ, Wilsnack R, Strand M. Rapid screening of monoclonal antibodies: New 'microstick' radioimmunoassay Journal of Immunological Methods. 58: 285-292. PMID 6833770 DOI: 10.1016/0022-1759(83)90356-3  1
1983 Krakow JS, Scheinberg DA, Strand M. A microradioiodination method for detection of nanogram amounts of proteins resolved by sodium dodecyl sulfate-polyacrylamide gel electrophoresis Journal of Virological Methods. 7: 273-278. PMID 6677646 DOI: 10.1016/0166-0934(83)90079-4  1
1983 Scheinberg DA, Strand M. Kinetic and Catabolic Considerations of Monoclonal Antibody Targeting in Erythroleukemic Mice Cancer Research. 43: 265-272. PMID 6571707  1
1982 Scheinberg DA, Strand M, Gansow OA. Tumor imaging with radioactive metal chelates conjugated to monoclonal antibodies. Science (New York, N.Y.). 215: 1511-3. PMID 7199757  0.52
1982 Scheinberg DA, Strand M. Leukemic cell targeting and therapy by monoclonal antibody in a mouse model system Cancer Research. 42: 44-49. PMID 6947860  1
1981 Scheinberg DA, Strand M. 55,000-Dalton, retrovirus-associated, cell membrane glycoprotein: Purification and quantitative measurements of expression in viruses, cells, and tissues Molecular and Cellular Biology. 1: 144-152. PMID 6965096  1
1981 Scheinberg DA, Strand M. A brain membrane protein similar to the rat src gene product Proceedings of the National Academy of Sciences of the United States of America. 78: 55-59. PMID 6264448  1
1980 Scheinberg DA, Strand M. Transformation-related proteins associated with Kirsten sarcoma virus Virology. 106: 335-348. PMID 6254255  1
Show low-probability matches.